LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
![Foto de LUIS GONZAGA](/img/nophoto.png)
![Foto de AstraZeneca (United Kingdom)](/img/noimage_org.png)
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (14)
2024
-
Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835
-
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study
Molecular Cancer, Vol. 23, Núm. 1
2022
-
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1415-1427
-
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
ESMO Open, Vol. 7, Núm. 2
-
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311
-
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
JTO Clinical and Research Reports, Vol. 3, Núm. 6
-
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
ESMO Open, Vol. 7, Núm. 2
2021
-
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 1, pp. 51-65
-
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
International Journal of Clinical Oncology, Vol. 26, Núm. 6, pp. 1073-1082
-
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867
-
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
Future Oncology, Vol. 17, Núm. 10, pp. 1165-1184
2018
-
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
The Lancet Oncology, Vol. 19, Núm. 4, pp. 521-536
2017
-
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
New England Journal of Medicine, Vol. 377, Núm. 20, pp. 1919-1929
2010
-
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer
Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 6, pp. 2664-2671